In order to evaluate the efficacy and safety of serine-threonine kinase（AKT） inhibitors （Capivasertib and Ipatasertib） in patients with HR+/HER2-breast cancer or metastatic triple negative breast cancer （TNBC），a comprehensive search of randomized clinical trials related to AKT inhibitors was conducted through PubMed，Embase，and the Cochrane Library. Five studies involving a total of 1304 patients were included. Outcomes such as progression-free survival （PFS），adverse events （AEs），overall survival （OS），duration of response （DOR），objective response rate （ORR），and clinical benefit rate （CBR） were analyzed using Review Manager 5.4.1. The results demonstrate that patients treated with AKT inhibitors show a significant improvement in PFS compared to those not receiving AKT inhibitors （MD=2.39；95%CI：[1.06，3.73]；P=0.000 5；I²=55%）. However，the incidence of certain severe AEs increases in patients treated with AKT inhibitors，such as infections （OR=1.72；95%CI：[1.09，2.72]；P=0.02；I²=0） and hyperglycemia （OR=3.07；95% CI：[1.36，6.93]；P=0.007；I²=63%）. These findings indicate that AKT inhibitors significantly prolong survival in patients with metastatic TNBC and HR+/HER2-breast cancer. Nevertheless，the occurrence of AEs （e.g.，infections，hyperglycemia） during AKT inhibitor treatment suggests that clinicians should use these agents cautiously and judiciously based on individual patient conditions.